Wednesday, April 4, 2012

Joseph F. Woody and Lisa N. Colleran to Join Board of Directors of Parent Company of KCI and LifeCell


Ronald A. Matricaria to Step Down from Board Following Transition Period




SAN ANTONIO - Wednesday, April 4th 2012 [ME NewsWire]

(BUSINESS WIRE)-- The parent company of Kinetic Concepts, Inc. (KCI) and LifeCell Corporation today announced that Joseph F. “Joe” Woody and Lisa N. Colleran will join the parent company’s board of directors. Additionally, Ronald A. Matricaria has stepped down from the board as of March 31. Joe Woody serves as KCI's president and CEO, while Lisa Colleran serves as president and CEO of LifeCell.

“We will benefit greatly from the strategic insight and operational experience Joe and Lisa provide as they join the board of directors,” said Buddy Gumina, a member of the board of directors. “Their contributions will be important as KCI and LifeCell chart their course to accelerated growth and profitability. We thank Ron Matricaria for his counsel during this transition period. As we have established a new corporate governance structure and analyzed strategic paths forward for KCI and LifeCell, Ron's board service was extremely valuable.”

“KCI and LifeCell are companies with strong leadership and great potential,” said Ron Matricaria. “It was a pleasure to work with the board and senior management during this transition phase, and I am confident that both companies will be successful in executing on their strategic plans.”

Woody has more than 20 years experience in the healthcare sector. He joined KCI as President of its Active Healing Solutions business in November 2011, and was named president and CEO of KCI in January. Prior, Woody served as Global President, Vascular Therapies for Covidien. At Covidien, he was responsible for the $2.6 billion acquisition and integration of ev3. Previously, Woody served as Global President, Smith & Nephew Advanced Wound Management and held other leadership positions at Alliance Imaging, Inc., Acuson and GE Medical Systems.

Colleran has served as president of LifeCell since 2008, and was appointed as CEO in January. Under her leadership, LifeCell has experienced significant growth and doubled its revenue. Colleran joined LifeCell in 2002 and has held several leadership positions including Senior Vice President, Commercial Operations and Vice President, Marketing and Business Development. Previously, Colleran spent 20 years at Baxter Healthcare Corporation in various roles in sales, marketing, business development and general management including Vice President of Marketing for Baxter's U.S. Renal business and Vice President/General Manager of the company's Renal Pharmaceuticals business.

KCI and LifeCell are privately owned by a consortium consisting of Apax Partners and controlled affiliates of the Canada Pension Plan Investment Board and Public Sector Pension Investment Board.

About KCI

Kinetic Concepts, Inc. is a leading global medical technology company devoted to the discovery, development, manufacture and marketing of innovative, high-technology therapies and products for the wound care and therapeutic support system markets. Headquartered in San Antonio, Texas, KCI has significantly advanced the science of wound healing over the course of more than three decades. KCI’s success can be traced to a history deeply rooted in innovation and a passion for significantly improving patient outcomes while reducing the overall cost of care for patients around the world. KCI’s proprietary Negative Pressure Technologies have revolutionized the way in which caregivers treat a wide variety of wound types. The V.A.C.® Therapy System has been used on more than 6 million wounds worldwide. Additional information about KCI and its products is available at www.KCI1.com.

About LifeCell

LifeCell Corporation, based in Branchburg, NJ, is a leader in regenerative medicine, develops and markets innovative tissue repair products for the reconstructive, orthopedic and urogynecologic biosurgery markets. LifeCell™ products include Strattice™ Reconstructive Tissue Matrix and AlloDerm® Regenerative Tissue Matrix for plastic, reconstructive, and general surgical applications; Cymetra® Regenerative Tissue Matrix, a particulate form of AlloDerm® Tissue Matrix suitable for injection; Repliform® Regenerative Tissue Matrix for urogynecologic surgical procedures; GraftJacket® and Conexa™ for orthopedic surgical procedures; and the SPY® Elite System for the visualization and evaluation of tissue perfusion. Additional information about LifeCell and its products is available at www.LifeCell.com.

Photos/Multimedia Gallery Available: http://www.businesswire.com/cgi-bin/mmg.cgi?eid=50228131&lang=en

Contacts

Kinetic Concepts, Inc.

For Media:

Kevin Belgrade, 210-216-1236

kevin.belgrade@kci1.com



For Investors:

Kent Tuholsky, 210-255-6547

kent.tuholsky@kci1.com

No comments:

Post a Comment